Full name
A Multicenter, Randomized, Double-Blind, Placebo-controlled Study to Assess the Efficacy and Safety of Treatment With Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection on Antiretroviral Treatment
NCT Number
NCT06497504
Geography
US
Non-US
Locations
Canada, South Africa, United States
Primary Endpoints
- Percentage of participants achieving HBV virologic response at 36 weeks after scheduled end of study treatment in absence of rescue medication. At study week 60
External Link
https://clinicaltrials.gov/study/NCT06497504
Order
6
Disease
Version
Phase
2